title: JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
abstract: Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.
authors.affiliation: VIB Center for the Biology of the Disease, Leuven, Belgium. sandrine.degryse@cme.vib-kuleuven.be.|KU Leuven Center for Human Genetics, Leuven, Belgium. sandrine.degryse@cme.vib-kuleuven.be.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Degryse
authors.affiliation: VIB Center for the Biology of the Disease, Leuven, Belgium. jan.cools@cme.vib-kuleuven.be.|KU Leuven Center for Human Genetics, Leuven, Belgium. jan.cools@cme.vib-kuleuven.be.|, Herestraat 49 (Box 602), 3000, Leuven, Belgium. jan.cools@cme.vib-kuleuven.be.
authors.forename: Jan
authors.initials: J
authors.lastname: Cools
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D053613:Janus Kinase 1 / Q000235:genetics*; D051379:Mice; D009857:Oncogenes; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D018121:Receptors, Cytokine; D015398:Signal Transduction
chemical_list: D018121:Receptors, Cytokine; C507904:JAK1 protein, human; D053613:Janus Kinase 1